Objectives: Tracking vaccine reactions and adverse events during a large-scale vaccination program such as the recent smallpox program or a pandemic flu outbreak will be a challenge. We report on vaccine reaction data collected using a novel telephone-and web-based electronic reporting system. The system was used to monitor vaccinees during the U.S. Army's smallpox vaccination campaign, which was part of the national program to prepare against biological attack. In addition, we report on the time course of events after smallpox vaccination based on the self-reported data and evaluate the validity and reliability of self-reported take information after smallpox vaccination.
ing for and handling a pandemic influenza outbreak.2
While vaccination for influenza is not as complicated as smallpox vaccination, the plan recognizes that adverse events will need to be tracked and reported in the case of an influenza pandemic.2 It is not clear if VAERS will be sufficient for this purpose.
Recent advances in telephone and web-based data col lection can streamline the process of monitoring vaccina tion reactions. Electronic reports were analyzed for site progression and compared with the health professional's assessment of vaccination response. The CDC definition of a take or "major reaction" is "a pustular lesion or an area of defi nite induration or congestion surrounding a central le sion, which can be a scab or an ulcer."' To maintain con sistency with that definition, a "bump," "reddish blister,"
or "whitish blister" had to be reported in the electronic self-reports to be considered a take for purposes of this analysis. To be considered a nonresponder (nontake), a vaccinee had to make a report of "none" or "colored spot" at least once on or after day 6 after vaccination (the first day recommended by the World Health Organiza tion [WHO] for take checks) without reporting further progression to bump, blister, or scab.
Statistical Methods
We used Chi-square tests and two-sample /-tests to compare demographic characteristics across different population groups. To compare the incidence of specific symptom reporting between first-time vaccinees and revaccinees, logistic regression models were used. Nega tive binomial regression models were used to compare revaccinees and first-time vaccinees regarding total num ber of distinct symptoms. Similarly, for total number of symptoms per report, due to the skewed distribution of the reports, categories were formed and multinomial re gression models were used. To compare timing of vac cine-site appearances and selected symptoms between re vaccinees and first-time vaccinees. time-to-event models, specifically the Cox proportional hazards model, were used. All of these regression models included gender, race, outpatient clinic, military rank, and revaccination status as independent variables. Age could not be in cluded in these models due to high collinearity with revaccination status. All statistical procedures were imple mented using SAS (SAS System version 8.2, Cary. NC).
RESULTS
Use of the System A total of 1,649 vaccinees volunteered to use the elec tronic monitoring system. Most were from Fort Hood (n = 715) or the Pentagon (n = 822). Unfortunately, be cause the system was implemented during the prepara tion for the war in Iraq, the number of people who were approached and declined to participate was not collected.
Most of those who declined stated that they were deploy ing within a week and would not be able to fully partici pate. Demographic characteristics of volunteers from Forts Belvoir, Bragg, and Hood were similar and are re ported in aggregate as "Army posts" (Table 1 ). Volun teers from the Pentagon were more likely to be officers. electronic data were available, but a take determination
was not recorded in the DoD clinic vaccination records, and data were considered "missing."
The DoD take records and the interpretation of elec tronic reports do not match for 8 cases for whom both selfreport and take-check data are available. Two vaccinees whose DoD records indicated the vaccine did not take had electronic reports that met the definition for take. In one of these two cases, the clinic's take check was probably per formed before the recommended time frame of 6-8 days,
in that on day 4 the vaccination site was read as "no take."
but the vaccinee made an electronic report of a bump on day 5 and continued to report through the scab falling off.
The other vaccinee also reported the full progression of site appearance, from bump through scab falling off, and the take check was performed on day 10. We were unable to determine why the health professional take assessment for this person does not match the electronic records. We Number of reports 25 Figure 1 . Reporting Rates. The number of reports made by vaccinees is graphed as a percentage of vaccinees who signed up for the electronic monitoring system. The mean number of reports made per user was 6.8 ± 6.2 (mean ± SD). and the median number of reports was 5; 73.4% of reports were made on the web, 15.3% were made by calling into the system, and 11.3% were made directly by the call center. reported anything other than none (no reaction) or col ored spot, and all reported at least once on or after day 8, the last day recommended for a take check.
Progression of Vaccination Site and Symptoms
Electronic records of vaccinees who had a take and whose vaccination/revaccination status was known were analyzed for progression of their vaccination site. We Comparisons are from regression models that adjust for gender, race, clinic site, and rank. and 7 for revaccinees and days 8-10 for first-time vaccinees. As was the case with site progression, the average first day that most symptoms were reported was earlier for revaccinees than first-time vaccinees (joint ache. p = 0.01; itching, local rash, warmth, muscle ache, and swollen lymph nodes, p < 0.01; pain, leaking fluid, and swelling./j< 0.001).
Of the 1.254 users, 113 (9.0%) made at least one report that triggered an automatic message to a healthcare pro fessional at their vaccination clinic. Forty-four vaccinees (3.5%) reported chest pain, and 77 (6.1 %) reported being extremely concerned about their vaccination. The authors do not have follow-up information on the clinical course of these patients, but they were included in other surveil lance efforts. 3 
DISCUSSION
Advances in technology have the capacity to revolu tionize both clinical care and public health. We found that recipients of smallpox vaccine were able to accu rately assess their reaction to smallpox vaccine and to report it using telephone-and web-based technology.
We believe that such emerging technologies can play°an important role in the consideration of future vaccination campaigns. Even putting bioterrorism aside, it is not un likely that a novel infectious disease or pandemic flu will emerge as a major public health challenge in the fu ture and that a large vaccination campaign could be re Specifically with regard to smallpox, adverse events from the recent smallpox vaccination campaign have been documented for both the military and civilian populations."1 In some cases. limited symptom data also have been reported.'-7 However, other than a report of 48 vaccinees with potential superinfection.8 this is the first detailed report of the progression of the vaccination site and symptoms, contrasting first-time vaccinees and re vaccinees in this contemporary cohort. The vaccine reac tion progressed more quickly in rcvaccinees than in first- lime vaccinees, while first-time vaccinees were more likely to report symptoms including pain, rash, and swollen lymph nodes.
We found that overall use of the electronic monitoring system was modest but that the sensitivity and positive predictive value of self-report of a vaccine take was quite high. If the reporting frequency could be improved, clin ics could rely on an electronic monitoring system to mon itor vaccine take among their clients. With this cohort, the electronic system could have reduced the number of return take-check visits by 73%. In addition, the system is designed with the ability to automatically notify a healthcare professional when a vaccinee reports a symp tom of concern, such as chest pain. These results also reinforce the importance of perform ing the take check after sufficient time for the vaccination reaction to occur. On at least one occasion, a vaccinee re turned for a take check on day 4 postvaccination. before the take was apparent physically. The vaccination site progressed to a white blister by day 6 and would proba bly have been correctly interpreted as a take at that time. 
